ZA991539B - Oral Formulation for hyrophilic drugs. - Google Patents

Oral Formulation for hyrophilic drugs.

Info

Publication number
ZA991539B
ZA991539B ZA9901539A ZA991539A ZA991539B ZA 991539 B ZA991539 B ZA 991539B ZA 9901539 A ZA9901539 A ZA 9901539A ZA 991539 A ZA991539 A ZA 991539A ZA 991539 B ZA991539 B ZA 991539B
Authority
ZA
South Africa
Prior art keywords
hyrophilic
drugs
oral formulation
oral
formulation
Prior art date
Application number
ZA9901539A
Other languages
English (en)
Inventor
Mou Ying Fu Lu
Walter Dziki
Zheng Wang
John F Bauer
Victor E Taylor
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Lab filed Critical Abbott Lab
Publication of ZA991539B publication Critical patent/ZA991539B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ZA9901539A 1998-02-26 1999-02-25 Oral Formulation for hyrophilic drugs. ZA991539B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US3120498A 1998-02-26 1998-02-26

Publications (1)

Publication Number Publication Date
ZA991539B true ZA991539B (en) 1999-08-25

Family

ID=21858162

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA9901539A ZA991539B (en) 1998-02-26 1999-02-25 Oral Formulation for hyrophilic drugs.

Country Status (5)

Country Link
AR (1) AR015531A1 (fr)
AU (1) AU2870899A (fr)
CO (1) CO4970788A1 (fr)
WO (1) WO1999043299A2 (fr)
ZA (1) ZA991539B (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2153819B1 (fr) 2000-07-14 2012-09-05 Allergan, Inc. Utilisation d'un agent augmentant la solubilité dans une composition aqueuse comprenant tartrate de brimonidine
CN101897704B (zh) 2000-07-14 2014-10-29 阿勒根公司 含有α-2肾上腺素能激动剂的组合物
US8858961B2 (en) 2000-07-14 2014-10-14 Allergan, Inc. Compositions containing alpha-2-adrenergic agonist components
ES2385240B1 (es) 2010-07-26 2013-09-23 Gp-Pharm, S.A. Cápsulas de principios activos farmacéuticos y ácidos grasos poliinsaturados para el tratamiento de enfermedades de la próstata.
CN116270492A (zh) * 2023-03-30 2023-06-23 北京博恩特药业有限公司 一种注射用醋酸亮丙瑞林缓释微球及其制备方法和用途

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06510046A (ja) * 1991-08-26 1994-11-10 アボツト・ラボラトリーズ 治療薬の舌下または頬投与のための組成物及び方法
JPH11292787A (ja) * 1995-08-15 1999-10-26 Asahi Chem Ind Co Ltd 生理活性ペプチドを含有する経粘膜投与製剤
US5853740A (en) * 1996-08-07 1998-12-29 Abbott Laboratories Delivery system for pharmaceutical agents encapsulated with oils

Also Published As

Publication number Publication date
AR015531A1 (es) 2001-05-02
CO4970788A1 (es) 2000-11-07
AU2870899A (en) 1999-09-15
WO1999043299A2 (fr) 1999-09-02
WO1999043299A3 (fr) 1999-11-04

Similar Documents

Publication Publication Date Title
ZA993338B (en) Pharmaceutical formulations.
ZA200202480B (en) Oral dosage forms.
HK1034455A1 (en) Oral pharmaceutical extended release dosage form.
ZA975673B (en) Solid oral dosage forms.
ZA962338B (en) Oral 2-methyl-thieno-benzodiazepine formulation.
HK1042245A1 (en) Pharmaceutical moxifloxacin preparation.
HUP0102483A3 (en) Pharmaceutical compositions containing androst-5-ene-3betha,17betha-diol
HK1048253A1 (en) Oral formulations for anti-tumor compounds.
HK1038884A1 (en) Medicinal compositions.
ZA200104280B (en) Pharmaceutical combination preparations.
GB9810886D0 (en) Pharmaceutical compounds
MXPA01012478A (es) Formulaciones farmaceuticas mejoradas.
ZA200005510B (en) Pharmaceutical composition.
ZA982112B (en) Rapamycin formulations for oral administration.
AU2564399A (en) Isoflavanoid formulations for oral administration
HK1040488A1 (en) Pharmaceutical formulations.
ZA985095B (en) Rapamycin formulations for oral administration.
ZA991539B (en) Oral Formulation for hyrophilic drugs.
HK1044117A1 (en) Pharmaceutical composition.
GB9817650D0 (en) Oral formulation
ZA99890B (en) Pharmaceutical compositions.
ZA99678B (en) 11-Qcetyl-12, 13-dioxabicyclo[8.2.1]-tridecenone derivatives, processes for the preparation thereof and medicaments containing these compounds.
GB9822333D0 (en) Pharmaceutical formulation
ZA994697B (en) Pharmaceutical formulation.
AU2156800A (en) Oral antiestrogen pharmaceutical composition